Johnson & Johnson (BVC:JNJCO)
Colombia · Delayed Price · Currency is COP | Market Cap | 2,124.36T +42.7% |
| Revenue (ttm) | 354.45T +7.9% |
| Net Income | 77.39T -3.5% |
| EPS | 31,763.55 -3.9% |
| Shares Out | n/a |
| PE Ratio | 27.45 |
| Forward PE | 22.02 |
| Dividend | 19,861.91 (2.22%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | 3 |
| Open | n/a |
| Previous Close | 894,960 |
| Day's Range | n/a |
| 52-Week Range | 621,460 - 935,660 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 15, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson announces FDA approval for THERMOCOOL SMARTTOUCH SF
Johnson & Johnson announced that the U.S. Food and Drug Administration approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an integrated catheter ablation solution that enables electrophysiolo...
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform.
Johnson & Johnson price target raised to $284 from $283 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $284 from $283 and keeps an Overweight rating on the shares. Biotech could benefit from…
Johnson & Johnson price target raised to $298 from $285 at Citi
Citi raised the firm’s price target on Johnson & Johnson to $298 from $285 and keeps a Buy rating on the shares. For Q2 earnings season, given “the skittish trading…
Jim Cramer says these are the 5 stocks to buy during this market rotation
CNBC's Jim Cramer said investors should use the latest market rotation as an opportunity to buy high-quality companies that were swept lower by broad institutional selling. He highlighted Johnson & Jo...
Johnson & Johnson price target raised to $290 from $280 at HSBC
HSBC raised the firm’s price target on Johnson & Johnson to $290 from $280 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted…
Johnson & Johnson presents new Imaavy data at EAN 2026 Congress
Johnson & Johnson announced new data across 12 abstracts at the European Academy of Neurology 2026 Congress that offer additional insight into the use of IMAAVY throughout clinically relevant points…
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+ a , anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disea...
Johnson & Johnson price target raised to $270 from $266 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $270 from $266 and keeps a Buy rating on the shares ahead of the company kicking…
Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe
Johnson & Johnson announced the commercial launch of the Dual Energy Thermocool Smarttouch SF Platform in Europe.
Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson today announced the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe, expanding physician access to a dual-...
3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026
Lowe’s ($LOW), Amcor ($AMCR), and Johnson & Johnson ($JNJ) are the three dividend aristocrat stocks with a Strong Buy rating on Wall Street and payout ratios of more than 50%,…
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billi...
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC...
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
STOCKHOLM, June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study sho...
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is...
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
Patients in the IMAAVY 30 mg/kg treatment group a achieved statistically significant durable hemoglobin response b , with mean hemoglobin improvement of at least 1 g/dL as early as Week 1 c More pat...
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
LOS ANGELES--(BUSINESS WIRE)-- #JohnsonJohnson--A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos...
Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
Joaquin Duato said finding a cure for certain cancers and turning others into chronic diseases is an achievable target for the coming decade.
Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong Q1 performance and robust growth are driven by double-digit product launches in immunology and oncology, with TREMFYA, ICOTYDE, and INLEXZO leading momentum. Pipeline innovation and strategic acquisitions position the portfolio for continued expansion and leadership.
Johnson & Johnson to Buy Firefly Bio for $1 Billion
Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker's oncology pipeline.
Johnson & Johnson to buy Firefly Bio for $1 billion
Johnson & Johnson said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks to expand its cancer drug pipeline.